On January 8, 2026, MediLink Therapeutics signed an exclusive license agreement with Roche to develop and commercialize YL201, an investigational ADC (antibody-drug conjugate) targeting the B7H3 protein in the treatment of various types of solid tumors[1]. The contract covers the world market, excluding mainland China, Hong Kong and Macau[1]. MediLink will receive an initial payment of $570 million from Roche, along with additional milestone payments and sales royalties upon drug approval[1]. YL201 received FDA Breakthrough Therapy designation and rare disease designations in small cell lung, nasopharyngeal carcinoma, and esophageal carcinoma in June 2025[2]. The drug is currently being investigated in international clinical trials in several advanced solid tumors, with preliminary data showing promising results, including survival in second-line small cell lung cancer patients[2]. This contract follows the successful collaboration from January 2024 on the development of the drug YL211 and represents a deepening of the mutual cooperation between the two companies[1].